Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
FMC Pharma is devoted to the treatment of osteoarthritis through the development of products, marketing methodologies and out-licensing opportunities. More
New pyridinic sulfonamide derivatives for the treatment and/or prevention of diseases such as inflammation, arthrosis, cancer and angiogenesis and for other pathologies in which they can play a role as COX-2 selective inhibitors. More
This invention concerns a new approach to the treatment of rheumatoid arthritis (RA) by "tolerogenic vaccination" with small interfering RNA (siRNA) technology. More
Displaying 1..10 of 22 -
per page
Next page
Order by